NDATOPICALGEL
Approved
Oct 2008
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONEXTON is a fixed-dose topical gel combining clindamycin phosphate (lincosamide antibacterial) and benzoyl peroxide (oxidizing bactericidal agent) for the treatment of acne vulgaris. The dual mechanism targets bacterial growth and inflammatory pathways while promoting keratolysis. It represents a well-established combination therapy in dermatology.
$0.415MPart D
PeakStable
3.3 years to LOEPeak-stage product with modest Part D volume indicates a mature, stable franchise with limited growth opportunity; commercial teams focus on maintenance and loyalty rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
Started Jan 2017
22 enrolled
Actinic Keratosis
Why This Matters for Your Career
Worked on ONEXTON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.